The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis

Seminars in Nephrology

Volumn 35, Issue 5, 2015, Pages 455-464

  Clark, Marcus R ^a,b   Trotter, Kimberly ^a   Chang, Anthony ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adaptive immunity; Innate immunity; Lupus nephritis; Tubulointerstitial inflammation

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; DISEASE ASSOCIATION; GLOMERULONEPHRITIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; AUTOIMMUNITY; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; KIDNEY; LUPUS NEPHRITIS; NEPHRITIS, INTERSTITIAL; PATHOLOGY;

IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; GLOMERULONEPHRITIS; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; KIDNEY; LUPUS NEPHRITIS; NEPHRITIS, INTERSTITIAL;

EID: 84945941223     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.08.007     Document Type: Review

References (118)

1. Mok C., Tang S.S. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 2004, 117:791-795.
2. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003, 82:299-308.
3. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
4. McLaughlin J., Bombardier C., Farewell V.T., Gladman D.D., Urowitz M.B. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994, 37:559-567.
5. Cook R., Gladman D.D., Pericak D., Urositz M.B. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000, 27:1892-1895.
6. Ginzler E., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
7. Appel G., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112. Aspreva Lupus Management Study Group.
8. Flanc R., Roberts M.A., Strippoli G.F., Chadban S.J., Kerr P.G., Atkins R.C. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004, 2004. CD0002922.
9. Chan T.M. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015, 11:46-56.
10. Korbet S., Schwartz M.M., Evans J., Lewis E.J. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007, 18:244-254.
11. Donadio J.J., Hart G.M., Bergstralh E.J., Holley K.E. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995, 4:109-115.
12. Neumann K., Wallace D.J., Azen C., Nessim S., Fichman M., Metzger A.L., et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995, 25:47-55.
13. Hsieh C., Chang A., Brandt D., Guttikonda R., Utset T.O., Clark M.R. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011, 63:865-874.
14. Faurschou M., Dreyer L., Kamper A.L., Starklint H., Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010, 62:873-880.
15. Austin H.R., Klippel J.H., Balow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614-619.
16. Ong L., Hooi L.S., Lim T.O., Goh B.L., Ahmad G., Ghazalli R., et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005, 10:504-510.
17. Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012, 64:797-808.
18. Weening J.J., D'Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004, 65:521-530.
19. Austin H.A., Muenz L.R., Joyce K.M., Antonovych T.A., Kullick M.E., Klippel J.H., et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983, 75:382-391.
20. Appel G., Cohen D.J., Pirani C.L., Meltzer J.I., Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987, 83:877-885.
21. Parichatikanond P., Francis N.D., Malasit P., Laohapand T., Nimmannit S., Singchoovong L., et al. Lupus nephritis: clinicopathological study of 162 cases in Thailand. J Clin Pathol 1986, 39:160-166.
22. Esdaile J.M., Levinton C., Federgreen W., Hayslett J.P., Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. QJM 1989, 72:779-833.
23. Williams W., Sargeant L.A., Smilkle M., Smith R., Edwards H., Shah D. The outcome of lupus nephritis in Jamaican patients. Am J Med Sci 2007, 334:426-430.
24. Dubois E.L. Lupus erythematosus 1974, WB Saunders, London. 2nd ed.
25. Park M.H., D'Agati V., Appel G.B., Pirani C.L. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986, 44:309-319.
26. Hill G.S., Delahousse M., Nochy D., Tomkiewicz E., Remy P., Mignon F., et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000, 58:1160-1173.
27. Schwartz M., Fennell J.S., Lewis E.J. Pathologic changes in the renal tubule in systemic lupus erythematosus. Hum Pathol 1982, 13:534-547.
28. Bohle A., Wehrmann M., Bogenschutz O., Batz C., Vogl W., Schmitt H., et al. The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 1992, 188:908-924.
29. Yu F., Wu L.H., Tan Y., Li L.-H., Wang C.-L., Wang C.-L., et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney Int 2010, 77:820-829.
30. Austin H.A., Boumpas D.T., Vaughan E.M., Balow J.E. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994, 45:544-550.
31. Nath K.A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992, 20:1-17.
32. Coppo R., D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005, 18:503-512.
33. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
34. Lin S.L., Castano A.P., Nowlin B.T., Lupher M.L., Duffield J.S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009, 183:6733-6743.
35. Ko G.J., Boo C.S., Jo S.K., Cho W.Y., Kim H.K. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 2008, 23:842-852.
36. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 115:56-65.
37. Nishida M., Hamaoka K. Macrophage phenotype and renal fibrosis in obstructive nephropathy. Nephron Exp Nephrol 2008, 110:e31-e36.
38. Wang Y., Wang Y.P., Zheng G., Lee V.W., Ouyang L., Chang D.H., et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007, 72:290-299.
39. Lebleu V.S., Sugimoto H., Miller C.A., Gattone V.H., Kalluri R. Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest 2008, 88:284-292.
40. Ascon M., Ascon D.B., Liu M., Cheadle C., Sarkar C., Racusen L., et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009, 75:526-535.
41. Burne-Taney M.J., Liu M., Ascon D., Molls R.R., Racusen L., Rabb H. Transfer of lymphocytes from mice with renal ischemia can induce albuminuria in naive mice: a possible mechanism linking early injury and progressive renal disease?. Am J Physiol Renal Physiol 2006, 291:F981-F986.
42. Davidson A., Aranow C. Lupus nephritis: lessons from murine models. Nat Rev Immunol 2010, 6:13-20.
43. Waldman M., Madaio M.P. Pathogenic autoantibodies in lupus nephritis. Lupus 2005, 14:19-24.
44. Kalaaji M., Fenton K.A., Mortensen E.S., Olsen R., Sturfelt G., Alm P., et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007, 71:664-672.
45. Steinmetz O.M., Velden J., Kneissler U., Marx M., Klein A., Helmchen U., et al. Analysis and classification of B-cell infiltrates in lupus and ANCA-associated vasculitis. Kidney Int 2008, 74:448-457.
46. Chang A., Henderson S.G., Brandt D., Liu N., Guttikonda R., Hsieh C., et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 2011, 186:1849-1860.
47. Satoskar A.A., Brodsky S.V., Nadasdy G., Bott C., Rovin B., Hebert L., et al. Discrepancies in glomerular and tubulointerstitial/vascular immune complex IgG subclasses in lupus nephritis. Lupus 2011, 20:1396-1403.
48. Jeruc J., Jurcic V., Vizjak A., Hvala A., Babic N., Kveder R., et al. Tubulo-interstitial involvement in lupus nephritis with emphasis on pathogenesis. Wien Klin Wochenschr 2000, 112:702-706.
49. Kinloch A.J., Chang A., Ko K., Henry Dunand C.J., Henderson S., Maienschein-Cline M., et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol 2014, 66:3359-3370.
50. Winchester R., Wiesendanger M., Zhang H.Z., Steshenko V., Peterson K., Geraldino-Pardilla L., et al. Immunologic characteristics of intrarenal T cells: trafficking of expanded CD8+ T cell beta-chain clonotypes in progressive lupus nephritis. Arthritis Rheum 2012, 64:1589-1600.
51. Eckes B., Colucci-Guyon E., Smola H., Nodder S., Babinet C., Krieg T., et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 2000, 113:2455-2462.
52. Mor-Vaknin N., Punturieri A., Sitwala K., Markovitz D.M. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003, 5:59-63.
53. Thiagarajan P.S., Yakubenko V.P., Elsori D.H., Yadav S.P., Willard B., Tan C.D., et al. Vimentin is an endogenous ligand for the pattern recognition receptor Dectin-1. Cardiovasc Res 2013, 99:494-504.
54. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71:886-892.
55. Nath D.S., Ilias B.G., Tiriveedhi V., Alur C., Phelan D., Eward G.A., et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010, 29:1277-1285.
56. Carter V., Shenton B.K., Jacques B., Turner D., Talbot D., Gupta A. Anti-vimentin antibody detection in recipients of heart-beating and non-heart beating donor kidneys. Transplant Proc 2005, 8:3269-3271.
57. Mahesh B., Leong J.S., McCormak A., Sarathchandra P., Holder A., Rose M.L. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007, 170:1415-1427.
58. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
59. Avalos A.M., Busconi L., Marshak-Rothstein A. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 2010, 43:76-83.
60. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
61. Liarski V., Kaverina N., Chang A., Brand D., Carlesso G., Utset T.O., et al. Quantitative cell distance mapping in human nephritis reveals organization of in situ adaptive immune responses. Sci Transl Med 2014, In press.
62. Fooksman D.R., Vardhana S., Vasiliver-Shamis G., Liese J., Blair D.A., Waite J., et al. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 2010, 28:79-105.
63. Adalid-Peralta L., Mathian A., Tran T., Delbos L., Durand-Gasselin I., Berrebi D., et al. Leukocytes and the kidney contribute to interstitial inflammation in lupus nephritis. Kidney Int 2008, 73:172-180.
64. Odegard J.M., DiPlacido L.D., Greenwald L., Kashgarian M., Kono D.H., Dong C., et al. ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J Immunol 2009, 182:4076-4084.
65. Cassese G., Lindenau S., de Boer B., Arce S., Hauser A., Riemekasten G., et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001, 31:2726-2732.
66. Sekine H., Watanabe H., Gilkeson G.S. Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol 2004, 172:3913-3921.
67. Woltman A.M., de Fijter J.W., Zuidwijk K., Vlug A.G., Bajema I.M., van der Kooij S.W., et al. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int 2007, 71:1001-1008.
68. Nelson P.J., Rees A.J., Griffin M.D., Hughes J., Kurts C., Duffield J. The renal mononuclear phagocytic system. J Am Soc Nephrol 2012, 23:194-203.
69. Dong X., Swaminathan S., Bachman L.A., Croatt A.J., Nath K.A., Griffin M.D. Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney Int 2005, 68:1096-1108.
70. Lukacs-Kornek V., Burgdorf S., Diehl L., Specht S., Kornek M., Kurts C. The kidney-renal lymph node-system contributes to cross-tolerance against innocuous circulating antigen. J Immunol 2008, 180:706-715.
71. Coates P.T., Duncan F.J., Colvin G.L., Wang Z., Zhahorchak A.F., Shufesky W.J., et al. In vivo-mobilized kidney dendritic cells are functionally immature, subvert alloreactive T-cell responses, and prolong organ allograft survival. Transplantation 2004, 77:1080-1089.
72. Scholz J.L., Lukas-Kornek V., Engel D.R., Specht S., Kiss E., Eitner F., et al. Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis. J Am Soc Nephrol 2008, 19:527-537.
73. Dong X., Bachman L.A., Miller M.N., Nath K.A., Griffin M.D. Dendritic cells facilitate accumulation of IL-17 T cells in the kidney following acute renal obstruction. Kidney Int 2008, 74:1294-1309.
74. Dong X., Swarminathan S., Bachman L.A., Croatt A.J., Nath K.A., Griffin M.D. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 2007, 71:619-628.
75. Tittel A.P., Heuser C., Ohliger C., Knoller P.A., Engel D.R., Kurts C. Kidney dendritic cells induce innate immunity against bacterial pyelonephritis. J Am Soc Nephrol 2011, 22:1435-1441.
76. Cao Q., Wang Y., Zheng D., Sun Y., Wang Y., Lee V.W.S., et al. IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against Adriamycin nephrosis. J Am Soc Nephrol 2010, 21:933-942.
77. Lee S., Huen S., Nishio H., Nishio S., Lee H.K., Choi B.S., et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 2011, 22:317-326.
78. Bethunaickan R., Berthier C.C., Ramanujam M., Sahu R., Zhang W., Sun Y., et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 2011, 186:4994-5003.
79. Berthier C.C., Bethunaickan R., Gonzalez-Riveria T., Nair V., Ramanujam M., Zhang W., et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 2012, 189:988-1001.
80. Fiore N., Castellano G., Blasi A., Capobianco C., Loverre A., Montinaro V., et al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol 2008, 45:259-265.
81. De Palma G., Castellano G., Del Prete A., Sozzani S., Fiore N., Loverre A., et al. The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int 2011, 79:1228-1235.
82. Aringer M., Graninger W.B., Steiner G., Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004, 50:3161-3169.
83. Boswell J.M., Yui M.A., Burt D.W., Kelley V.E. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988, 141:3050-3054.
84. Yokoyama H., Kreft B., Kelley V.R. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995, 47:122-130.
85. Brennan D.C., Yui M.A., Wuthrich R.P., Kelley V.E. Tumor necrosis factor and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989, 143:3470-3475.
86. Takemura T., Yoshioka K., Murakami K., Akano N., Okada M., Aya N., et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 1994, 424:459-464.
87. Herrera-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., Avalos-Diaz E. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 1998, 7:154-158.
88. Uppal S.S., Hayat S.J., Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18:690-697.
89. Aringer M., Houssiau F., Gordon C., Graninger W.B., Voll R.E., Rath E., et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48:1451-1454.
90. De Bandt M., Sibilia J., Le Loet X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7:R545-R551.
91. Soforo E., Baumgartner M., Francis L., Allam F., Phillips P.E., Perl A. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010, 37:204-205.
92. Campbell S., Burkly L.C., Gao H.X., Berman J.W., Su L., Browning B., et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006, 176:1889-1898.
93. Chicheportiche Y., Chicheportiche R., Sizing I., Thompson J., Benjamin C.B., Ambrose C., et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002, 4:126-133.
94. Zhao Z., Burkly L.C., Campbell S., Schwartz N., Molano A., Choudhury A., et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007, 179:7949-7958.
95. Lu J., Kwan B.C., Lai F.M., Choi P.C., Tam L.S., Li E.K., et al. Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology (Carlton) 2011, 16:426-432.
96. Schwartz N., Rubinstein T., Burkly L.C., Collins C.E., Blanco I., Su L., et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009, 11:R143.
97. El-Shehaby A., Darweesh H., El-Khatib M., Momtaz M., Marzouk S., El-Shaarawy N., et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011, 31:848-856.
98. Epstein F.H. Oxygen and renal metabolism. Kidney Int 1997, 51:381-385.
99. Bethunaickan R., Berthier C.C., Zhang W., Eksi R., Li H.D., Guan Y., et al. Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB x NZW)F1 and NZM2410 mice. Arthritis Rheum 2014, 66:2246-2258.
100. Bethunaickan R., Berthier C.C., Zhang W., Kretzler M., Davidson A. Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. PLoS One 2013, 8:e77489.
101. Berthier C.C., Bethunaickan R., Gonzalez-Rivera T., Nair V., Ramanujam M., Zhang W., et al. Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol 2012, 189:988-1001.
102. Gunaratnam L., Bonventre J.V. HIF in kidney disease and development. J Am Soc Nephrol 2009, 20:1877-1887.
103. Nangaku M., Eckardt K.U. Hypoxia and the HIF system in kidney disease. J Mol Med (Berl) 2007, 85:1325-1330.
104. Norman J.T., Stidwill R., Singer M., Fine L.G. Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action. Nephron Physiol 2003, 94:39-46.
105. Gagliardini E., Corna D., Zoja C., Sangalli F., Carrara F., Rossi M., et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009, 297:F1448-F1456.
106. Kimura K., Iwano M., Higgins D.F., Yamaguchi Y., Nakatani K., Harada K., et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008, 295:F1023-F1029.
107. Danobeitia J.S., Djamali A., Fernandez L.A. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair 2014, 7:16.
108. Zeisberg M., Neilson E.G. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010, 21:1819-1834.
109. Eddy A.A. Proteinuria and interstitial injury. Nephrol Dial Transplant 2004, 19:277-281.
110. Theilig F. Spread of glomerular to tubulointerstitial disease with a focus on proteinuria. Ann Anat 2010, 192:125-132.
111. Tang S., Leung J.C., Abe K., Chan K.W., Chan L.Y., Chan T.M., et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest 2003, 111:515-527.
112. Shimizu H., Maruyama S., Yuzawa Y., Kato T., Miki Y., Suzuki S., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003, 14:1496-1505.
113. Tesch G.H., Maifert S., Schwarting A., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999, 190:1813-1824.
114. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456.
115. Vernon K.A., Cook H.T. Complement in glomerular disease. Adv Chronic Kidney Dis 2012, 19:84-92.
116. Heymann F., Meyer-Schwesinger C., Hamilton-Williams E.E., Hammerich L., Panzer U., Kaden S., et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest 2009, 119:1286-1297.
117. Mori Y., Kishimoto N., Yamahara H., Kijima Y., Nose A., Uchiyama-Tanaka Y., et al. Predominant tubulointerstitial nephritis in a patient with systemic lupus nephritis. Clin Exp Nephrol 2005, 9:79-84.
118. Omokawa A., Wakui H., Okuyama S., Togashi M., Ohtani H., Komatsuda A., et al. Predominant tubulointerstitial nephritis in a patient with systemic lupus erythematosus: phenotype of infiltrating cells. Clin Nephrol 2008, 69:436-444.